Dental ImplantNCT03242330
Two-piece Versus Single-piece Patient-specific Titanium Subperiosteal Implants
A study testing Subperiosteal implant in people with Dental Implant, run by Cairo University at 1 site in Egypt.
Trial summary
The objective of this trial is to find out if there is a difference between single-piece and two-piece titanium patient-specific mandibular subperiosteal implants in terms of implant survival, patient satisfaction, and soft tissue dehiscence. Read more about this study
- Who is it for?
- Ages 50 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Dental Implant
- What is being tested?
- Subperiosteal implant
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 156 participants
- Where
- 1 siteEgypt
- Study dates
- Aug 2017to Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Completely edentulous male or female patients with atrophied mandibles between the ages of 50 to 75.
- Atrophic mandibular ridges in terms of width and height, impeding the possibility of placing a root form dental implant of at least 3mm in diameter and 8 mm in length.
- Completely edentulous patients (with the above mentioned criteria) who can't stand a soft-tissue supported mandibular denture.
Who cannot join
- Patients having a medical condition that absolutely contraindicates implant placement.
- Patients with uncontrolled diabetes, assessed by measuring glycosylated haemoglobin (HbA1c). Patients with an HbA1c level greater than 8 will be excluded.
- Potentially uncooperative patients who are not willing to go through the proposed interventions.
- Moderate-to-heavy daily smokers* (who report consuming at least 11 cigarettes/day).
- Patients who are satisfied with their soft-tissue supported mandibular denture.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Implant Survival in Two-piece Versus Single-piece Patient-specific Titanium Subperiosteal Implants in Atrophied Edentulous Mandibles: Randomized Clinical Trial
The objective of this trial is to find out if there is a difference between single-piece and two-piece titanium patient-specific mandibular subperiosteal implants in terms of implant survival, patient satisfaction, and soft tissue dehiscence. This is to enhance both surgical and prosthetic outcomes for the sake of improved implant longevity, soft tissue health and patient well-being.
Read the detailed description
After obtaining a thorough medical and dental history and performing necessary laboratory investigations, the following steps will be undertaken:
Preoperative prosthetic preparation:
- For eligible patients who are already wearing upper and lower complete dentures: The dentures will be checked for adaptation, fit, stability and occlusion.
- For eligible patients who are not wearing upper and lower complete dentures:
Preliminary alginate impressions will be made using a perforated stock tray for both the maxillary and mandibular arches. Impressions are then poured into dental stone to obtain the diagnostic models. Occlusion blocks will be constructed over the diagnostic models, followed by bite registration, try-in and delivery of upper and lower complete dentures.
Afterwards, approved complete dentures will be duplicated using laboratory condensation silicone to construct a radiographic stent. The radiographic stent is prepared by using a ratio of 3:1 acrylic resin to barium sulphate mixture, and then the patient is sent for a Cone Beam Computed Tomography (CBCT) scan.
CBCT scanning and virtual design of the patient-specific implant (PSI):
The CBCT scan of the patients - in the form of DICOM files - will be imported into surgical planning software (Mimics 19, Materialise, Leuven, Belgium). A segmentation process will be accomplished by using the two dimensional CT cuts to define the image thresholds based on Hounsfield's units, excluding soft tissue and only highlighting hard tissue (bone). The maxilla/mandible region will be further isolated by cropping and/or region-growing functions to remove artifacts and select only the area of interest, followed by the 3D calculation of the selected regions. The 3D models will be exported in standard triangulation language (STL) format.
The STL files will then be imported into computer-aided design (CAD) software (3-matic) in order to create the design of the PSI. The subperiosteal part of the PSI will be drawn on the surface of the region planned to receive the PSI and then extruded to a thickness of 2.5mm. The PSIs will be meshed out with 2.5 mm holes to be compatible with 2.0 mm fixation screws. For the single-piece PSI, the abutments will be placed, guided by the opposing teeth and the radio-opaque dentures. As for the two-piece PSI, the same design will be repeated without the addition of the abutment posts.
Fabrication of the patient-specific implant (PSI):
The STL file of the final design will be sent for 3D printing via additive manufacturing using selective laser sintering (SLS) machine from medical titanium grade (Ti-6Al-4V) Extra Low Interstitials (ELI).
PSI surface treatment:
The PSI will be subjected to acid etching following a protocol proposed by Juodzbalys et al to attain micro roughness on the fitting surface of the implant. The PSIs will be etched with sulfuric acid (H2SO4) for 72 hours followed by Hydrochloric acid (HCl) for 30 hours. After removal from the acids PSIs will be washed in distilled water.
Cleaning and sterilization:
Implants will be cleaned in an ultrasonic bath of absolute ethyl alcohol solution at ambient temperature for 30 minutes to ensure the removal of any residues on the fitting surface of the implant. After being thoroughly cleaned, the PSIs will be wrapped and sterilized using a class B autoclave.
Surgical phase:
For both groups, under general anesthesia; a mucosal incision 3-5 mm crestal to the vestibule will be made in the anterior region similar to the genioplasty incision, followed by dissection over the orbicularis oris and mentalis muscle and incising down to bone using a scalpel blade #15c mounted on a Bard-Parker® surgical blade handle size 3, to expose the proposed implant site. The incision will be completed posteriorly after localization of the mental nerves. After bone exposure the implant will be installed in place and fixed with 2.0mm grade 5 titanium screws.
For two-piece PSIs, the framework will be designed with 3-4 mm endosseous projections at the anticipated area where the final abutments will be fastened, guided by the position of the teeth in the proposed prosthetic set-up. The endosseous projections will be designed in order to accommodate the height of the internal connection that will receive the final abutment in a second-stage surgery. Unlike single piece PSIs, bone-supported surgical guides will be designed to aid in the placement and seating of the two-piece PSIs corresponding to the preplanned osteotomy sites. The flap will be sutured in two layers; the muscle layer will be closed with 3/0 poliglecaprone resorbable suture material and the mucosa with 4/0 Polypropylene non-resorbable suture material.
Postoperative care and instructions:
The intra oral wounds will be evaluated for any signs of bleeding, hematoma, infection, wound dehiscence or PSI exposure after 48 hours, then weekly till the end of the first month. The following medications will be administered:
Long acting corticosteroids: Methylprednisolone Acetate 40 mg/ml intramuscular injection single dose immediate postoperative.
Anti-inflammatory analgesic: Ketorolac tromethamine 30 mg/amp/2mL intramuscular injection every 12 hours for the first 24 hours followed by diclofenac potassium 50 mg tablets (every 8 hours for 4 days) Oral antibiotic: Ampicillin/sulbactam 375 mg tablets (every 8 hours for 10 days) Strict oral hygiene measures in the form of regular use of chlorohexidine Gluconate 125 mg/100 mL antiseptic mouth wash (every 8 hours for two weeks).
Prosthetic phase:
The steps of fabrication of the final prosthesis will be initiated 3 months after implant placement for both groups. For the single-piece PSI group, a closed impression will be made. For the two-piece PSI group, final abutments will be fastened to the corresponding connection in the framework in a second stage surgery, followed by a final closed impression a week later. The final restoration will be constructed from a high impact polymer composite (HIPC) material via computer numerically controlled (CNC) milling. Occlusal adjustments will be performed followed by temporary cementation for two weeks until a final approval is obtained from the patient. Later, the prosthesis will be cemented using glass ionomer self-cured luting cement.
- Conditions
- Dental Implant
- Being tested
- Subperiosteal implant
- Keywords
- Implant survival, Patient satisfaction
- Medical subject headings
- Patient Satisfaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Subperiosteal implantDevice
Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
| Study group | Role | What they receive |
|---|---|---|
| Two-piece subperiosteal implant | Experimental | The two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body. Receives: Device: Subperiosteal implant |
| Single-piece subperiosteal implant | Active comparator | The single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery. Receives: Device: Subperiosteal implant |
What is being measured
The primary outcome is the main question the study is designed to answer.
Implant survival
Implant survival will be assessed by evaluation of the following criteria:
- Persistent pain, and/or b) mobility and/or c) persistent exudate In case of presence of one or more of the previously mentioned criteria, implants will be regarded non-survived.
Presence of persistent pain either spontaneous or during function Presence of clinically detected mobility Evidence of infection in the form of pus formation or persistent inflammatory fluid exudate
Measured: 12 months (post-surgery)
Secondary outcomes (4)
Implant survival
Implant survival will be assessed by evaluation of the following criteria:
- Persistent pain, and/or b) mobility and/or c) persistent exudate In case of presence of one or more of the previously mentioned criteria, implants will be regarded non-survived.
Presence of persistent pain either spontaneous or during function Presence of clinically detected mobility Evidence of infection in the form of pus formation or persistent inflammatory fluid exudate
Measured: 6 months (post-surgery)
Implant survival
Implant survival will be assessed by evaluation of the following criteria:
- Persistent pain, and/or b) mobility and/or c) persistent exudate In case of presence of one or more of the previously mentioned criteria, implants will be regarded non-survived.
Presence of persistent pain either spontaneous or during function Presence of clinically detected mobility Evidence of infection in the form of pus formation or persistent inflammatory fluid exudate
Measured: 3 months (post-surgery)
Patient satisfaction
Patient satisfaction is regarded an indicator of quality of healthcare. In this trial, the numerical rating scale (NRS) for patient satisfaction will be used, where patients will be asked to rate their satisfaction on the NRS (11-point ordinal scale) by selecting a whole number (0-10 integers), from 0 (completely dissatisfied) to 10 (completely satisfied). Higher scores portray higher satisfaction.
Measured: At 1,3,6 and 12 months (after loading of final prosthesis)
Soft tissue dehiscence
The investigators will subjectively assess this outcome through clinical examination of the oral tissues. It will be a binary outcome dichotomized to presence or absence of soft tissue breakdown based on the clinical examination.
Measured: At 1,3,6 and 12 months (post-surgery)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2017
- Study startAug 2017 (estimated)
- Primary completionAug 2020 (estimated)
- Study completionDec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Dental ImplantStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 156 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mariam Ahmed Roshdy, Cairo University
- Investigators
- Mariam A. Roshdy, Principal investigator, Assistant lecturer, Department of Prosthodontics, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03242330
- Sponsor's protocol ID
- Cairo Uni
- Status last verified
- Aug 2017
- First submitted
- 31 Jul 2017
- Last updated
- 8 Aug 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sconzo J. The complete mandibular subperiosteal implant: an overview of its evolution. J Oral Implantol. 1998;24(1):14-5. doi: 10.1563/1548-1336(1998)242.0.CO;2. No abstract available.
PubMed 9759036Burns DR, Unger JW, Elswick RK Jr, Beck DA. Prospective clinical evaluation of mandibular implant overdentures: Part I--Retention, stability, and tissue response. J Prosthet Dent. 1995 Apr;73(4):354-63. doi: 10.1016/s0022-3913(05)80331-2.
PubMed 7783014Aras E, Sonmez M, Zora M, Basarir M, Kurtulmus H. The use of prefabricated titanium tissue abutments for the construction of a maxillary subperiosteal implant. J Oral Implantol. 2005;31(5):255-8. doi: 10.1563/1548-1336(2005)31[255:TUOPTT]2.0.CO;2.
PubMed 16265856OBWEGESER HL. Experiences with subperiosteal implants. Oral Surg Oral Med Oral Pathol. 1959 Jul;12(7):777-86. doi: 10.1016/0030-4220(59)90027-1. No abstract available.
PubMed 13674677The glossary of prosthodontic terms. J Prosthet Dent. 2005 Jul;94(1):10-92. doi: 10.1016/j.prosdent.2005.03.013. No abstract available.
PubMed 16080238Weiss CM, Reynolds T. A collective conference on the utilization of subperiosteal implants in implant dentistry. J Oral Implantol. 2000;26(2):127-8. doi: 10.1563/1548-1336(2000)262.0.CO;2. No abstract available.
PubMed 11831330Falomo OO, Hobkirk JA. A retrospective survey of patients treated with subperiosteal and endosseous implants. J Prosthet Dent. 1988 Nov;60(5):587-90. doi: 10.1016/0022-3913(88)90219-3. No abstract available.
PubMed 3058941Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005 Aug;14(7):798-804. doi: 10.1111/j.1365-2702.2005.01121.x.
PubMed 16000093Juodzbalys, G., M. Sapragoniene, and A. Wennerberg, New acid etched titanium dental implant surface. Stomatologija-Baltic Dental and Maxillofacial Journal, 2003. 5: p. 101-105.
Study at a glance
From the registry record, last updated by the sponsor on 8 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implant Survival in Two-piece Versus Single-piece Patient-specific Titanium Subperiosteal Implants in Atrophied Edentulous Mandibles: Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT03242330
- Acronym / sponsor ID
- Cairo Uni
- Conditions
- Dental Implant
- Keywords
- Implant survival, Patient satisfaction
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 156 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- Aug 2017 (estimated)
- Primary completion
- Aug 2020 (estimated)
- Study completion
- Dec 2020 (estimated)
- First posted
- 8 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this trial is to find out if there is a difference between single-piece and two-piece titanium patient-specific mandibular subperiosteal implants in terms of implant survival, patient satisfaction, and soft tissue dehiscence. This is to enhance both surgical and prosthetic outcomes for the sake of improved implant longevity, soft tissue health and patient well-being.
Detailed description
After obtaining a thorough medical and dental history and performing necessary laboratory investigations, the following steps will be undertaken:
Preoperative prosthetic preparation:
- For eligible patients who are already wearing upper and lower complete dentures: The dentures will be checked for adaptation, fit, stability and occlusion.
- For eligible patients who are not wearing upper and lower complete dentures:
Preliminary alginate impressions will be made using a perforated stock tray for both the maxillary and mandibular arches. Impressions are then poured into dental stone to obtain the diagnostic models. Occlusion blocks will be constructed over the diagnostic models, followed by bite registration, try-in and delivery of upper and lower complete dentures.
Afterwards, approved complete dentures will be duplicated using laboratory condensation silicone to construct a radiographic stent. The radiographic stent is prepared by using a ratio of 3:1 acrylic resin to barium sulphate mixture, and then the patient is sent for a Cone Beam Computed Tomography (CBCT) scan.
CBCT scanning and virtual design of the patient-specific implant (PSI):
The CBCT scan of the patients - in the form of DICOM files - will be imported into surgical planning software (Mimics 19, Materialise, Leuven, Belgium). A segmentation process will be accomplished by using the two dimensional CT cuts to define the image thresholds based on Hounsfield's units, excluding soft tissue and only highlighting hard tissue (bone). The maxilla/mandible region will be further isolated by cropping and/or region-growing functions to remove artifacts and select only the area of interest, followed by the 3D calculation of the selected regions. The 3D models will be exported in standard triangulation language (STL) format.
The STL files will then be imported into computer-aided design (CAD) software (3-matic) in order to create the design of the PSI. The subperiosteal part of the PSI will be drawn on the surface of the region planned to receive the PSI and then extruded to a thickness of 2.5mm. The PSIs will be meshed out with 2.5 mm holes to be compatible with 2.0 mm fixation screws. For the single-piece PSI, the abutments will be placed, guided by the opposing teeth and the radio-opaque dentures. As for the two-piece PSI, the same design will be repeated without the addition of the abutment posts.
Fabrication of the patient-specific implant (PSI):
The STL file of the final design will be sent for 3D printing via additive manufacturing using selective laser sintering (SLS) machine from medical titanium grade (Ti-6Al-4V) Extra Low Interstitials (ELI).
PSI surface treatment:
The PSI will be subjected to acid etching following a protocol proposed by Juodzbalys et al to attain micro roughness on the fitting surface of the implant. The PSIs will be etched with sulfuric acid (H2SO4) for 72 hours followed by Hydrochloric acid (HCl) for 30 hours. After removal from the acids PSIs will be washed in distilled water.
Cleaning and sterilization:
Implants will be cleaned in an ultrasonic bath of absolute ethyl alcohol solution at ambient temperature for 30 minutes to ensure the removal of any residues on the fitting surface of the implant. After being thoroughly cleaned, the PSIs will be wrapped and sterilized using a class B autoclave.
Surgical phase:
For both groups, under general anesthesia; a mucosal incision 3-5 mm crestal to the vestibule will be made in the anterior region similar to the genioplasty incision, followed by dissection over the orbicularis oris and mentalis muscle and incising down to bone using a scalpel blade #15c mounted on a Bard-Parker® surgical blade handle size 3, to expose the proposed implant site. The incision will be completed posteriorly after localization of the mental nerves. After bone exposure the implant will be installed in place and fixed with 2.0mm grade 5 titanium screws.
For two-piece PSIs, the framework will be designed with 3-4 mm endosseous projections at the anticipated area where the final abutments will be fastened, guided by the position of the teeth in the proposed prosthetic set-up. The endosseous projections will be designed in order to accommodate the height of the internal connection that will receive the final abutment in a second-stage surgery. Unlike single piece PSIs, bone-supported surgical guides will be designed to aid in the placement and seating of the two-piece PSIs corresponding to the preplanned osteotomy sites. The flap will be sutured in two layers; the muscle layer will be closed with 3/0 poliglecaprone resorbable suture material and the mucosa with 4/0 Polypropylene non-resorbable suture material.
Postoperative care and instructions:
The intra oral wounds will be evaluated for any signs of bleeding, hematoma, infection, wound dehiscence or PSI exposure after 48 hours, then weekly till the end of the first month. The following medications will be administered:
Long acting corticosteroids: Methylprednisolone Acetate 40 mg/ml intramuscular injection single dose immediate postoperative.
Anti-inflammatory analgesic: Ketorolac tromethamine 30 mg/amp/2mL intramuscular injection every 12 hours for the first 24 hours followed by diclofenac potassium 50 mg tablets (every 8 hours for 4 days) Oral antibiotic: Ampicillin/sulbactam 375 mg tablets (every 8 hours for 10 days) Strict oral hygiene measures in the form of regular use of chlorohexidine Gluconate 125 mg/100 mL antiseptic mouth wash (every 8 hours for two weeks).
Prosthetic phase:
The steps of fabrication of the final prosthesis will be initiated 3 months after implant placement for both groups. For the single-piece PSI group, a closed impression will be made. For the two-piece PSI group, final abutments will be fastened to the corresponding connection in the framework in a second stage surgery, followed by a final closed impression a week later. The final restoration will be constructed from a high impact polymer composite (HIPC) material via computer numerically controlled (CNC) milling. Occlusal adjustments will be performed followed by temporary cementation for two weeks until a final approval is obtained from the patient. Later, the prosthesis will be cemented using glass ionomer self-cured luting cement.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Two-piece subperiosteal implant | Experimental | Device: Subperiosteal implantThe two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body. |
| Single-piece subperiosteal implant | Active comparator | Device: Subperiosteal implantThe single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery. |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Completely edentulous male or female patients with atrophied mandibles between the ages of 50 to 75.
- Atrophic mandibular ridges in terms of width and height, impeding the possibility of placing a root form dental implant of at least 3mm in diameter and 8 mm in length.
- Completely edentulous patients (with the above mentioned criteria) who can't stand a soft-tissue supported mandibular denture.
Key exclusion criteria (5 listed)
- Patients having a medical condition that absolutely contraindicates implant placement.
- Patients with uncontrolled diabetes, assessed by measuring glycosylated haemoglobin (HbA1c). Patients with an HbA1c level greater than 8 will be excluded.
- Potentially uncooperative patients who are not willing to go through the proposed interventions.
- Moderate-to-heavy daily smokers* (who report consuming at least 11 cigarettes/day).
- Patients who are satisfied with their soft-tissue supported mandibular denture.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Subperiosteal implantSubperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted. | Device | Single-piece subperiosteal implant, Two-piece subperiosteal implant |
Primary outcome
Implant survival
Time frame: 12 months (post-surgery)
Implant survival will be assessed by evaluation of the following criteria: a) Persistent pain, and/or b) mobility and/or c) persistent exudate In case of presence of one or more of the previously mentioned criteria, implants will be regarded non-survived. Presence of persistent pain either spontaneous or during function Presence of clinically detected mobility Evidence of infection in the form of pus formation or persistent inflammatory fluid exudate
4 secondary outcomes
Implant survival
Time frame: 6 months (post-surgery)
Implant survival
Time frame: 3 months (post-surgery)
Patient satisfaction
Time frame: At 1,3,6 and 12 months (after loading of final prosthesis)
Soft tissue dehiscence
Time frame: At 1,3,6 and 12 months (post-surgery)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Aug 2017.
- Background: PubMed 9759036Sconzo J. The complete mandibular subperiosteal implant: an overview of its evolution. J Oral Implantol. 1998;24(1):14-5. doi: 10.1563/1548-1336(1998)242.0.CO;2. No abstract available.
- Background: PubMed 7783014Burns DR, Unger JW, Elswick RK Jr, Beck DA. Prospective clinical evaluation of mandibular implant overdentures: Part I--Retention, stability, and tissue response. J Prosthet Dent. 1995 Apr;73(4):354-63. doi: 10.1016/s0022-3913(05)80331-2.
- Background: PubMed 16265856Aras E, Sonmez M, Zora M, Basarir M, Kurtulmus H. The use of prefabricated titanium tissue abutments for the construction of a maxillary subperiosteal implant. J Oral Implantol. 2005;31(5):255-8. doi: 10.1563/1548-1336(2005)31[255:TUOPTT]2.0.CO;2.
- Background: PubMed 13674677OBWEGESER HL. Experiences with subperiosteal implants. Oral Surg Oral Med Oral Pathol. 1959 Jul;12(7):777-86. doi: 10.1016/0030-4220(59)90027-1. No abstract available.
- Background: PubMed 16080238The glossary of prosthodontic terms. J Prosthet Dent. 2005 Jul;94(1):10-92. doi: 10.1016/j.prosdent.2005.03.013. No abstract available.
- Background: PubMed 11831330Weiss CM, Reynolds T. A collective conference on the utilization of subperiosteal implants in implant dentistry. J Oral Implantol. 2000;26(2):127-8. doi: 10.1563/1548-1336(2000)262.0.CO;2. No abstract available.
- Background: PubMed 3058941Falomo OO, Hobkirk JA. A retrospective survey of patients treated with subperiosteal and endosseous implants. J Prosthet Dent. 1988 Nov;60(5):587-90. doi: 10.1016/0022-3913(88)90219-3. No abstract available.
- Background: PubMed 16000093Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005 Aug;14(7):798-804. doi: 10.1111/j.1365-2702.2005.01121.x.
- BackgroundJuodzbalys, G., M. Sapragoniene, and A. Wennerberg, New acid etched titanium dental implant surface. Stomatologija-Baltic Dental and Maxillofacial Journal, 2003. 5: p. 101-105.
- Individual participant dataSharing planned: No
Related trials for Dental Implant
Not yet recruitingPhase 1/2
Effect of Povidone Iodine on the Dental Implant Internal Surface Microbiome
Dental Implant
Recruiting
The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation
Alveolar Bone Loss, Edentulism Nos
RecruitingObservational study
Changes in Oral Health-related Quality of Life (OHRQoL) During Full Arch Implant Treatment
Edentulous Mouth, Quality of Life
Not yet recruitingObservational study
Plaque and Bleeding on Probing Around Implants Supporting Fixed Full-Arch Dental Prostheses
Peri-Implant Health
Enrolling by invitation
Investigation of the Effect of Horizontal Platelet Rich Fibrin Placed in Tooth Extraction Sockets on Bone Formation
Tooth Loss, Dental Implant Failed
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mariam A. Roshdy principal investigator
Assistant lecturer, Department of Prosthodontics, Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Subperiosteal implant in people with Dental Implant, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Implant survival (time frame: 12 months (post-surgery)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03242330, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2017.